Uche Mordi

Also affiliated with Gilead Sciences (United Kingdom), Gilead Sciences (United States)

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Evaluating the Fiscal Impact of Antiretroviral Therapy for the Management of HIV in the United States 1987–2023”.

Evaluating the Fiscal Impact of Antiretroviral Therapy for the Management of HIV in the United States 1987–2023

ClinicoEconomics and Outcomes Research(2025)10.2147/ceor.s520050

N/A

0DataRank · unranked

7 citations

Uche Mordi, James Jarrett, Ryan Thaliffdeen, Paresh Chaudhari, Mark P. Connolly +3 more

Modeling the Public Health Impact of Improved Antiretroviral Therapy Restart Patterns Among People with HIV Who Have Discontinued Treatment

Journal of Health Economics and Outcomes Research(2026)10.36469/001c.159112

N/A

0DataRank · unranked

0 citations

Cillian Copeland, Uche Mordi, James Jarrett, Rui Martins, Mark P. Connolly +2 more